ステロイド性骨粗鬆症に投与されたデノスマブの関与が考えられた顎骨骨髄炎の1例

抄録

Denosumab, the human monoclonal antibody to RANKL, was approved for the treatment of osteoporosis with its ease of administration once every 6 months.
We report a case of a 74-year-old male patient, who has developed chronic osteomyelitis of the jaw possibly associated with a single denosumab dose for the treatment of glucocorticoid-induced osteoporosis. Extensive osteolytic changes associated with diffuse sclerosis and sequester formation were found in the left lower molar region on panoramic X-ray and CT. Subsequently, sequestration was also observed in the left upper molar edentulous region.
Based on this case report, we suggest that medical-dental collaboration, sharing of the administered medication record and enlightenment of patients are important for the treatment of anti-resorptive agent-related osteomyelitis/osteonecrosis of the jaw. Additionally, it is suggested that teriparatide might lead to an early healing process.